Safety of in utero and neonatal antiretroviral exposure: Cognitive and academic outcomes in HIV-exposed, Uninfected Children 5-13 Years of Age

Pediatric Infectious Disease Journal

Volumn 33, Issue 11, 2014, Pages 1128-1133

  Nozyce, Molly L ^a   Huo, Yanling ^b   Williams, Paige L ^b   Kapetanovic, Suad ^c   Hazra, Rohan ^d   Nichols, Sharon ^e   Hunter, Scott ^f   Smith, Renee ^g   Seage, George R ^b   Sirois, Patricia A ^h  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^h TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Academic achievement; ARV; Children; Cognition; Hiv; Neurodevelopment

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DIDANOSINE; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ADOLESCENT; ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; ARTICLE; ASSESSMENT OF HUMANS; CHILD; CHILD SAFETY; COGNITION; COHORT ANALYSIS; DEMOGRAPHY; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERFORMANCE INTELLIGENCE QUOTIENT; PERINATAL DRUG EXPOSURE; PREMATURITY; PRENATAL EXPOSURE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SMALL FOR DATE INFANT; WECHSLER ABBREVIATED SCALE OF INTELLIGENCE; WECHSLER INDIVIDUAL ACHIEVEMENT TEST, SECOND EDITION; WECHSLER INTELLIGENCE SCALE; CHILD DEVELOPMENT; DRUG COMBINATION; DRUG EFFECTS; EDUCATIONAL STATUS; HIV INFECTIONS; INTELLIGENCE; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRESCHOOL CHILD; PREVENTION AND CONTROL; TRANSMISSION; VERTICAL TRANSMISSION;

ADOLESCENT; ANTI-RETROVIRAL AGENTS; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; EDUCATIONAL STATUS; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INTELLIGENCE; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS; WECHSLER SCALES;

EID: 84925936953     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000410     Document Type: Article

References (39)

1. Griner R, Williams PL, Read JS, et al.; Pediatric HIV/AIDS Cohort Study. In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States. AIDS Patient Care STDS. 2011;25:385-394.
2. Heidari S, Mofenson L, Cotton M F, et al. Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr. 2011;57:290-296.
3. Whitmore SK, Zhang X, Taylor AW, et al. Estimated number of infants born to HIV-infected women in the United States and five dependent areas, 2006. J Acquir Immune Defic Syndr. 2011;57:218-222.
4. WHO. Mother-to-child transmission of HIV data and statistics. Available at: http://www.who.int/hiv/topics/mtct/data/en/index1.html. Accessed January 28, 2014.
5. Ivanovic J, Nicastri E, Anceschi MM, et al.; Pregnancy And Newborn Clinical Outcome Group in HIV Infection (PANCOH). Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women. Curr HIV Res. 2009;7:620-625.
6. Thorne C, Newell ML. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern? Drug Saf. 2007;30: 203-213.
7. Divi RL, Leonard SL, Walker BL, et al. Erythrocebus patas monkey offspring exposed perinatally to NRTIs sustain skeletal muscle mitochondrial compromise at birth and at 1 year of age. Toxicol Sci. 2007;99:203-213.
8. Divi RL, Einem TL, Fletcher SL, et al. Progressive mitochondrial compromise in brains and livers of primates exposed in utero to nucleoside reverse transcriptase inhibitors (NRTIs). Toxicol Sci. 2010;118:191-201.
9. Gerschenson M, Nguyen V, Ewings EL, et al. Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine. AIDS Res Hum Retroviruses. 2004;20:91-100.
10. Poirier MC, Olivero OA, Walker DM, et al. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol Appl Pharmacol. 2004;199:151-161.
11. Calamandrei G, Valanzano A, Puopolo M, et al. Developmental exposure to the antiretroviral drug zidovudine increases brain levels of brain-derived neurotrophic factor in mice. Neurosci Lett. 2002;333:111-114.
12. Fundarò C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS. 2002;16:299-300.
13. Rajlakshmi C, Bhattacharyya A, Trigunayat A, et al. Neurobehavioral profile of F1 and F2 generation mice following one stage zidovudine exposure through pregnancy and lactation. Ann Neurosc. 2008;15:69-74.
14. Venerosi A, Valanzano A, Puopolo M, et al. Neurobehavioral effects of prenatal exposure to AZT: a preliminary investigation with the D1 receptor agonist SKF 38393 in mice. Neurotoxicol Teratol. 2005;27:169-173.
15. Alimenti A, Forbes JC, Oberlander T F, et al. A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy. Pediatrics. 2006;118:e1139-e1145.
16. Culnane M, Fowler M, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA. 1999;281:151-157.
17. Kammerer B, Kacanek D, Mayondi G, et al. Pediatric neurodevelopmental functioning following in utero exposure to triple-NRTI-vs. PI-based ART in a randomized trial, Botswana [abstract WEPE208]. XIX International AIDS Conference, Washington, D.C, July 22-27, 2012.
18. Lindsey JC, Malee KM, Brouwers P, et al.; PACTG 219C Study Team. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. Pediatrics. 2007;119:e681-e693.
19. Williams PL, Marino M, Malee K, et al.; PACTG 219C Team. Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants. Pediatrics. 2010;125:e250-e260.
20. Sirois PA, Huo Y, Williams PL, et al.; Pediatric HIVAIDS Cohort Study. Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants. Pediatr Infect Dis J. 2013;32:648-655.
21. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084-1089.
22. Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS. 2007;21:929-938.
23. Le Doaré K, Bland R, Newell ML. Neurodevelopment in children born to HIV-infected mothers by infection and treatment status. Pediatrics. 2012;130:e1326-e1344.
24. Brackis-Cott E, Kang E, Dolezal C, et al. The impact of perinatal HIV infection on older school-aged children's and adolescents' receptive language and word recognition skills. AIDS Patient Care STDS. 2009;23:415-421.
25. Smith R, Chernoff M, Williams PL, et al.; Pediatric HIV/AIDS Cohort Study (PHACS) Team. Impact of HIV severity on cognitive and adaptive functioning during childhood and adolescence. Pediatr Infect Dis J. 2012;31:592-598.
26. Ciaranello AL, Seage GR 3rd, Freedberg KA, et al. Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity. AIDS. 2008;22:2359-2369.
27. Lanphear B P, Hornung R, Khoury J, et al. Low-level environmental lead exposure and children's intellectual function: an international pooled analysis. Environ Health Perspect. 2005;113:894-899.
28. Bellinger DC. Very low lead exposures and children's neurodevelopment. Curr Opin Pediatr. 2008;20:172-177.
29. Bradley RH, Corwyn RF. Socioeconomic status and child development. Annu Rev Psychol. 2002;53:371-399.
30. Brooks-Gunn J, Duncan GJ. The effects of poverty on children. Future Child. 1997;7:55-71.
31. Wechsler Preschool and Primary Scales of Intelligence. Third Edition. San Antonio: The Psychological Corporation; 2002.
32. Wechsler Abbreviated Scale of Intelligence. San Antonio: The Psychological Corporation; 1999.
33. Wechsler Individual Achievement Test. Second Edition. Abbreviated. San Antonio: The Psychological Corporation; 2001.
34. Aidala A, Havens J, Mellins CA, et al. Development and validation of the Client Diagnostic Questionnaire (CDQ): a mental health screening tool for use in HIV/AIDS service settings. Psychol Health Med. 2004;9:362-379.
35. Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis. 2011;204:506-514.
36. Rice ML, Zeldow B, Siberry GK, et al.; Pediatric HIVAIDS Cohort Study (PHACS). Evaluation of risk for late language emergence after in utero antiretroviral drug exposure in HIV-exposed uninfected infants. Pediatr Infect Dis J. 2013;32:e406-e413.
37. Løhaugen GC, Østgård HF, Andreassen S, et al. Small for gestational age and intrauterine growth restriction decreases cognitive function in young adults. J Pediatr. 2013;163:447-453.
38. McLoyd VC. Socioeconomic disadvantage and child development. Am Psychol. 1998;53:185-204.
39. Breslau N, Chilcoat HD, Susser ES, et al. Stability and change in children's intelligence quotient scores: a comparison of two socioeconomically disparate communities. Am J Epidemiol. 2001;154:711-717.